Fluoroquinolone-resistant escherichia coli sequence type 131 isolates causing bloodstream infections in a canadian region with a centralized laboratory system: Rapid emergence of the H30-RX sublineage

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 5, 2014, Pages 2699-2703

  Peirano, Gisele ^a,b   Pitout, Johann D D ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE AMPC; EXTENDED SPECTRUM BETA LACTAMASE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; CANADA; CLINICAL FEATURE; ESCHERICHIA COLI; ESCHERICHIA COLI H 30; ESCHERICHIA COLI H 30 RX; ESCHERICHIA COLI SEQUENCE TYPE 131; GENE IDENTIFICATION; HEALTHCARE ASSOCIATED INFECTION; INFECTION RISK; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PUBLIC HEALTH PROBLEM; URINARY TRACT INFECTION; DRUG EFFECTS; ENZYMOLOGY; GENETICS; MICROBIAL SENSITIVITY TEST; PHENOTYPE; PLASMID;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; PLASMIDS;

EID: 84898619561     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00119-14     Document Type: Article

References (29)

1. Pitout JD. 2012. Extraintestinal pathogenic Escherichia coli: an update on antimicrobial resistance, laboratory diagnosisandtreatment. Expert Rev. Anti Infect. Ther. 10:1165-1176. http://dx.doi.org/10.1586/eri.12.110.
2. Foxman B. 2010. The epidemiology of urinary tract infection. Nat. Rev. Urol. 7:653-660. http://dx.doi.org/10.1038/nrurol.2010.190.
3. Pitout JD, Laupland KB. 2008. Extended-spectrum beta-lactamaseproducing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis. 8:159-166. http://dx.doi.org/10.1016/S1473-3099(08) 70041-0.
4. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. 2001. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin. Infect. Dis. 32:1162-1171. http://dx.doi.org/10.1086/319757.
5. Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, Citton R, D'Inzeo T, Fadda G, Cauda R, Spanu T. 2007. Predictors of mortality in patients with bloodstream infections caused by extendedspectrum- beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob. Agents Chemother. 51:1987-1994. http://dx.doi.org/10.1128/AAC.01509-06.
6. Peirano G, Pitout JD. 2010. Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. Int. J. Antimicrob. Agents 35:316-321. http://dx.doi.org/10.1016/j.ijantimicag. 2009.11.003.
7. Colpan A, Johnston B, Porter S, Clabots C, Anway R, Thao L, Kuskowski MA, Tchesnokova V, Sokurenko EV, Johnson Jr. 2013. Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. Clin. Infect. Dis. 57: 1256-1265. http://dx.doi.org/10.1093/cid/ cit503.
8. Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. 2010. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin. Infect. Dis. 51:286-294. http://dx.doi.org/10.1086/653932.
9. Peirano G, Richardson D, Nigrin J, McGeer A, Loo V, Toye B, Alfa M, Pienaar C, Kibsey P, Pitout JD. 2010. High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extendedspectrum-beta-lactamase-producing Escherichia coli isolates from Canada. Antimicrob. Agents Chemother. 54:1327-1330. http://dx.doi.org/10.1128/AAC.01338-09.
10. Banerjee R, Robicsek A, Kuskowski MA, Porter S, Johnston BD, Sokurenko E, Tchesnokova V, Price LB, Johnson Jr. 2013. Molecular epidemiology of Escherichia coli sequence type 131 and its H30 and H30-Rx subclones among extended-spectrum-beta-lactamase-positive and-negative E. coli clinical isolates from the Chicago region, 2007 to 2010. Antimicrob. Agents Chemother. 57:6385-6388. http://dx.doi.org/10.1128/AAC.01604-13.
11. Johnson JR, Tchesnokova V, Johnston B, Clabots C, Roberts PL, Billig M, Riddell K, Rogers P, Qin X, Butler-Wu S, Price LB, Aziz M, Nicolas-Chanoine MH, Debroy C, Robicsek A, Hansen G, Urban C, Platell J, Trott DJ, Zhanel G, Weissman SJ, Cookson BT, Fang FC, Limaye AP, Scholes D, Chattopadhyay S, Hooper DC, Sokurenko EV. 2013. Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli. J. Infect. Dis. 207:919-928. http://dx.doi.org/10. 1093/infdis/jis933.
12. Laupland KB, Gregson DB, Church DL, Ross T, Pitout JD. 2008. Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region. Clin. Microbiol. Infect. 14:1041-1047. http://dx.doi.org/10. 1111/j.1469-0691.2008.02089.x.
13. Peirano G, van der Bij AK, Gregson DB, Pitout JD. 2012. Molecular epidemiology over an 11-year period (2000 to 2010) of extendedspectrum beta-lactamase-producing Escherichia coli causing bacteremia in a centralized Canadian region. J. Clin. Microbiol. 50:294-299. http://dx.doi.org/10.1128/JCM. 06025-11.
14. Pitout JD, Gregson DB, Campbell L, Laupland KB. 2009. Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of communityacquired infections. Antimicrob. Agents Chemother. 53:2846-2851. http://dx.doi.org/10.1128/AAC.00247-09.
15. Russell JA. 2006. Management of sepsis. N. Engl. J. Med. 355:1699-1713. http://dx.doi.org/10.1056/NEJMra043632.
16. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, Lamm W, Clark C, MacFarquhar J, Walton AL, Reller LB, Sexton DJ. 2002. Health care-Associated bloodstream infections in adults: a reason to change the accepted definition of community-Acquired infections. Ann. Intern. Med. 137:791-797. http://dx.doi.org/10.7326/0003-4819-137-10-200211190-00007.
17. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing: twenty-second informational supplement. M100-S22. CLSI, Wayne, PA.
18. Pitout JD, Le PG, Moore KL, Church DL, Gregson DB. 2010. Detection of AmpC beta-lactamases in Escherichia coli, Klebsiella spp., Salmonella spp. and Proteus mirabilis in a regional clinical microbiology laboratory. Clin. Microbiol. Infect. 16:165-170. http://dx.doi.org/10.1111/j.1469-0691.2009.02756. x.
19. Pitout JD, Church DL, Gregson DB, Chow BL, McCracken M, Mulvey MR, Laupland KB. 2007. Molecular epidemiology of CTX-M-producing Escherichia coli in the Calgary Health Region: emergence of CTX-M-15-producing isolates. Antimicrob. Agents Chemother. 51:1281-1286. http://dx.doi.org/10.1128/AAC.01377- 06.
20. Poirel L, Dortet L, Bernabeu S, Nordmann P. 2011. Genetic features of blaNDM-1-positive Enterobacteriaceae. Antimicrob. Agents Chemother. 55: 5403-5407. http://dx.doi.org/10.1128/AAC.00585-11.
21. Robicsek A, Strahilevitz J, Sahm DF, Jacoby GA, Hooper DC. 2006. qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States. Antimicrob. Agents Chemother. 50:2872-2874. http://dx.doi.org/10.1128/ AAC.01647-05.
22. Park CH, Robicsek A, Jacoby GA, Sahm D, Hooper DC. 2006. Prevalence in the United States of aac(6=)-Ib-cr encoding a ciprofloxacinmodifying enzyme. Antimicrob. Agents Chemother. 50:3953-3955. http://dx.doi.org/10.1128/AAC.00915- 06.
23. Yamane K, Wachino J, Suzuki S, Arakawa Y. 2008. Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan. Antimicrob. Agents Chemother. 52:1564-1566. http://dx.doi.org/10.1128/AAC.01137-07.
24. Clermont O, Dhanji H, Upton M, Gibreel T, Fox A, Boyd D, Mulvey MR, Nordmann P, Ruppe E, Sarthou JL, Frank T, Vimont S, Arlet G, Branger C, Woodford N, Denamur E. 2009. Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J. Antimicrob. Chemother. 64:274-277. http://dx.doi.org/10.1093/jac/dkp194.
25. Price LB, Johnson JR, Aziz M, Clabots C, Johnston B, Tchesnokova V, Nordstrom L, Billig M, Chattopadhyay S, Stegger M, Andersen PS, Pearson T, Riddell K, Rogers P, Scholes D, Kahl B, Keim P, Sokurenko EV. 2013. The epidemic of extended-spectrum-beta-lactamaseproducing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30-Rx. mBio 4:e00377-13. http://dx.doi.org/10.1128/mBio.00377-13.
26. Van der Bij AK, Peirano G, Pitondo-Silva A, Pitout JD. 2012. The presence of genes encoding for different virulence factors in clonally related Escherichia coli that produce CTX-Ms. Diagn. Microbiol. Infect. Dis. 72:297-302. http://dx.doi.org/10.1016/j.diagmicrobio.2011.12.011.
27. Warburg G, Korem M, Robicsek A, Engelstein D, Moses AE, Block C, Strahilevitz J. 2009. Changes in aac(6=)-Ib-cr prevalence and fluoroquinolone resistance in nosocomial isolates of Escherichia coli collected from 1991 through 2005. Antimicrob. Agents Chemother. 53:1268-1270. http://dx.doi.org/10. 1128/AAC.01300-08.
28. Kim HB, Park CH, Kim CJ, Kim EC, Jacoby GA, Hooper DC. 2009. Prevalence of plasmid-mediated quinolone resistance determinants over a 9-year period. Antimicrob. Agents Chemother. 53:639-645. http://dx.doi.org/10.1128/AAC.01051- 08.
29. Matsumura Y, Yamamoto M, Nagao M, Ito Y, Takakura S, Ichiyama S. 2013. Association of fluoroquinolone resistance, virulence genes, and IncF plasmids with extended-spectrum-beta-lactamase-producing Escherichia coli sequence type 131 (ST131) and ST405 clonal groups. Antimicrob. Agents Chemother. 57:4736-4742. http://dx.doi.org/10.1128/AAC.006 41-13.